Literature DB >> 33629127

Comparison of the short-term outcomes of laparoscopic and open total or proximal gastrectomy using the transorally inserted anvil (OrVilTM) for the proximal reconstruction: a propensity score matching analysis.

Fanling Hong1, Yinkui Wang1, Yan Zhang1, Shuangxi Li1, Fei Shan1, Yongning Jia1, Ziyu Li2, Jiafu Ji1.   

Abstract

PURPOSE: To compare the short-term surgical outcomes of laparoscopic and open total/proximal gastrectomy using transorally inserted anvil (OrVilTM).
METHOD: Patients diagnosed with gastric cancer and underwent total or proximal gastrectomy using OrVilTM for reconstruction were included. Clinical and pathological characteristics, as well as postoperative outcomes, were analyzed. Propensity score matching was used to balance baseline factors.
RESULTS: From April 2012 to April 2020, 199 patients at our center were included. A total of 166 underwent open total or proximal gastrectomy (OTG/OPG), and 33 underwent laparoscopic total or proximal gastrectomy (LTG/LPG). Twenty-seven patients from each group were paired with propensity score matching. The operation time was significantly shorter in the OTG/OPG group after matching. The overall complication rate and the incidence of each complication did not show significant differences between the two groups before and after matching.
CONCLUSION: LTG/LPG and OTG/OPG using OrVilTM for the alimentary tract reconstruction are both feasible and can achieve similar short-term outcomes.

Entities:  

Keywords:  Alimentary tract reconstruction; Gastrectomy; Propensity score matching; Transorally inserted anvil

Year:  2021        PMID: 33629127     DOI: 10.1007/s00423-021-02126-8

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  1 in total

1.  Outcome of esophagojejunostomy during totally laparoscopic total gastrectomy: a single-center retrospective study.

Authors:  Yukiharu Hiyoshi; Eiji Oki; Koji Ando; Shuhei Ito; Hiroshi Saeki; Masaru Morita; Hideo Baba; Yoshihiko Maehara
Journal:  Anticancer Res       Date:  2014-12       Impact factor: 2.480

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.